Description: Beta-lactams provide superior outcomes in comparison to vancomycin in treating methicillin-susceptible Staphylococcus aureus (MSSA) infections complicated by bacteremia. However, approximately 11% of inpatients report a penicillin (PCN) allergy when it is estimated that only 1% of the general population is truly allergic to the antibiotic. Consequently, many patients may be receiving suboptimal treatment for a serious infection with a high mortality rate. This study evaluated the cost-effectiveness of penicillin skin testing (PST) in adult inpatients self-reporting PCN allergy and undergoing treatment for MSSA bacteremia. A decision analytic model was developed comparing an acute care PST intervention to a scenario with no confirmatory allergy testing. This dataset includes a decision analytic model diagram, model inputs, and an Excel file with MSSA bacteremia model parameters and probabilistic simulation calculations.

Subject Domain

Keywords

Restrictions: Unrestricted access
Instructions: All relevant data are within the paper and its Supporting Information File; Access via Article
Decision analytic model diagram, input table, and results

Associated Publications

Data Type

Software Used

Microsoft Excel

Study Type

Observational

Dataset Format(s)

Microsoft Excel

Penicillin Skin Testing in Methicillin-Sensitive Staphylococcus aureus Bacteremia: A Cost-Effectiveness Analysis